UNASSIGNED: Eligible patients received NIPS every 3 weeks. Gastrectomy was performed for patients who met the criteria of conversion surgery. The primary end point was 1-year overall survival (OS) rate. Secondary end points were the response rate, toxic effects, conversion surgery outcomes and median survival time (MST).
UNASSIGNED: Sixty-seven patients were enrolled. The primary endpoint was achieved with 1-year OS rate reached 67.2% (95% CI, 56.8%-79.4%). Conversion surgery was performed in 42 patients (62.9%), and R0 resection was achieved in 23 patients (54.8%) with the MST of 31.3 months (95% CI, 24.3-38.3). And the MST was 19.3 months (95% CI, 16.4-22.2) for all patients. Toxicity and surgical complications were well-tolerated. Moreover, sex, R0 resection, pathological nodal stage and tumor regression grade (TRG) were independent prognostic factors for patients who underwent conversion surgery.
UNASSIGNED: The NIPS is effective and safe in treating GC patients with peritoneal metastasis. Male patients, patients who underwent R0 resection, patients with ypN0-1 or TRG 1 after conversion surgery are more likely to benefit from the NIPS.
UNASSIGNED: http://www.chictr.org.cn/, identifier https://clinicaltrials.gov/ (
■符合条件的患者每3周接受一次NIPS。对符合转换手术标准的患者进行胃切除术。主要终点是1年总生存率(OS)。次要终点是反应率,毒性作用,转换手术结果和中位生存时间(MST)。
■纳入67例患者。主要终点为1年OS率达到67.2%(95%CI,56.8%-79.4%)。42例患者(62.9%)进行了转换手术,23例患者(54.8%)完成R0切除,MST为31.3个月(95%CI,24.3-38.3)。所有患者的MST为19.3个月(95%CI,16.4-22.2)。毒性和手术并发症耐受性良好。此外,性别,R0切除,病理淋巴结分期和肿瘤消退分级(TRG)是中转手术患者的独立预后因素.
■NIPS在治疗有腹膜转移的GC患者中是有效且安全的。男性患者,接受R0切除的患者,转换手术后患有ypN0-1或TRG1的患者更有可能从NIPS中获益.
■http://www.chictr.org.cn/,标识符https://clinicaltrials.gov/(